Equities

Grand Pharmaceutical Group Ltd

Grand Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.05
  • Today's Change0.06 / 1.50%
  • Shares traded1.70m
  • 1 Year change-21.36%
  • Beta0.5830
Data delayed at least 15 minutes, as of Apr 24 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.

  • Revenue in HKD (TTM)10.53bn
  • Net income in HKD1.88bn
  • Incorporated1995
  • Employees10.53k
  • Location
    Grand Pharmaceutical Group LtdUnits 3302The Center, 99 Queen's Road Central Hong KongHKG
  • Phone+852 28663718
  • Fax+852 28662521
  • Websitehttp://chinagrandpharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cansino Biologics Inc373.42m-1.60bn8.46bn1.49k--0.7979--22.65-6.50-6.501.5123.060.03322.370.4626249,945.80-18.93-4.27-26.69-5.60-253.78---569.97-27.721.86--0.3381---66.52213.94-63.04--30.60--
InnoCare Pharma Ltd798.95m-682.90m8.60bn1.07k--0.9622--10.76-0.4049-0.40490.47354.390.0731.393.39---6.38-13.41-8.08-15.3682.6185.99-87.42-172.164.13--0.1582--18.09240.3628.80------
Keymed Biosciences Inc383.06m-388.75m9.04bn897.00--2.77--23.59-1.49-1.491.4511.680.09060.731426.14427,046.90-9.16---10.05--89.59---101.04--9.18--0.123--253.87---16.63------
Luye Pharma Group Ltd6.65bn576.17m9.97bn5.01k17.220.69397.431.500.15390.15391.783.820.2472.423.24--2.172.803.564.4568.4470.538.7810.391.212.680.3837--2.703.50-11.94-16.39----
AIM Vaccine Co Ltd1.28bn-1.41bn10.16bn1.62k--2.58--7.91-1.16-1.161.063.25------791,013.90--------75.88---164.24--0.7583-11.540.3158---6.06---307.07------
Yichang Hec Changjiang Pharmactcl Co Ltd6.81bn2.16bn10.63bn4.62k4.931.244.371.562.452.457.749.760.51113.624.001,474,557.0015.078.0324.4611.8179.2179.9729.4820.801.309.320.2475--68.0820.182,501.2416.15----
SciClone Pharmaceuticals (Holdings) Ltd3.41bn1.21bn11.30bn1.05k9.663.2014.753.311.861.865.255.630.75853.563.833,251,194.0026.9727.0933.3436.3274.6776.0635.5535.434.5027.950.01--14.7617.5031.1615.96----
Zai Lab Ltd2.09bn-2.62bn11.98bn2.18k--1.88--5.73-2.71-2.712.166.420.23642.515.38---29.66-37.72-34.97-42.7264.0864.75-125.46-282.444.41--0.00--24.03360.0324.51---3.45--
Simcere Pharmaceutical Group Ltd7.15bn773.23m13.62bn7.03k18.001.7612.301.910.29010.29012.742.970.61063.532.651,017,268.006.6010.178.9415.6075.4378.8210.8017.501.870.97290.1652--4.497.92-23.22-0.5213----
SSY Group Ltd6.46bn1.32bn13.92bn5.60k10.592.017.962.150.44270.44272.172.330.56373.003.011,154,109.0011.5910.5115.5814.0356.0158.7220.5718.621.6029.610.31738.560.45059.1017.447.663.9413.56
3SBio Inc8.46bn1.68bn13.98bn5.41k8.480.90536.721.650.67550.67553.466.330.34261.586.751,562,614.006.957.449.039.2984.9882.9120.3021.502.265.260.2266--13.8411.26-19.133.94----
Grand Pharmaceutical Group Ltd10.53bn1.88bn14.16bn10.53k7.450.92186.191.350.53560.53563.004.330.46922.945.06999,581.408.4510.0911.6614.0161.9661.9718.0022.350.981923.210.183126.9510.1212.06-9.5921.41--24.77
The United Laboratories Intl. Hldgs Ltd.14.86bn2.92bn17.04bn15.00k5.831.244.821.151.611.618.187.580.68713.363.26990,922.9013.517.8920.5212.6446.1144.1719.6612.731.74--0.105515.5121.2212.8470.8531.66--14.67
Data as of Apr 24 2024. Currency figures normalised to Grand Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

3.64%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 Apr 202454.50m1.54%
Dimensional Fund Advisors LPas of 04 Apr 202422.79m0.64%
BlackRock Fund Advisorsas of 04 Apr 202417.10m0.48%
Bosera Asset Management Co., Ltd.as of 31 Dec 202212.45m0.35%
Principal Global Investors LLCas of 29 Feb 20245.69m0.16%
Lingohr & Partner Asset Management GmbHas of 31 Jan 20245.41m0.15%
BlackRock Advisors (UK) Ltd.as of 02 Apr 20243.75m0.11%
China Asset Management Co., Ltd.as of 30 Jun 20233.32m0.09%
American Century Investment Management, Inc.as of 04 Apr 20242.16m0.06%
E Fund Asset Management Co. Ltd.as of 30 Jun 20232.03m0.06%
More ▼
Data from 30 Jun 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.